Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel …
Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel …
BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. BDSI's pain franchise consists of three products, two of which utilize the patented BioErodible … An NDA for BUNAVAIL, a BEMA …
Read more on Sacramento Bee
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of …
BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. BDSI's pain franchise consists of three … Clonidine Topical Gel for the treatment of painful diabetic neuropathy is entering Phase 3 …
Read more on Wall Street Journal